Lexicon Pharmaceuticals (LXRX) PT Raised to $6 at Leerink Partners
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St climbs after August inflation report, oil price slide
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for 8% weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Piper Sandler Reiterates Overweight Rating on Lexicon Pharmaceuticals (LXRX)
October 17, 2024 7:53 AM EDTPiper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $10.00 price target on Lexicon Pharmaceuticals (NASDAQ: LXRX).
The analyst commented, "We were pleased to hear LXRX announce an exclusive licensing agreement with VTRS (covered by Amsellem) for sotagliflozin across all indications... More
H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX)
October 17, 2024 6:55 AM EDTH.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $10.00 price target on Lexicon Pharmaceuticals (NASDAQ: LXRX).
The analyst commented: "Yesterday, Lexicon announced a new partnership with Viatris Inc. (VTRS; not rated), giving Viatris the rights to commercialize Lexicons dual SGLT2/SGLT1 inhibitor, sotagliflozin, for all indications outside the U.S. and E.U. We welcome this development as it broadens sotas global commercialization potential, particularly with... More
Lexicon Pharma (LXRX) Announces Exclusive Licensing Agreement With Viatris (VTRS) for Sotagliflozin in All Markets Outside of the U.S. and Europe
October 16, 2024 4:35 PM EDTLexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Viatris Inc. (Nasdaq: VTRS) has obtained an exclusive license from Lexicon to commercialize sotagliflozin outside of the United States and Europe in all indications. Lexicon retains sole commercialization rights for sotagliflozin in all indications in the United States and Europe.
Sotagliflozin was approved by the U.S. Food and Drug Administration in May 2023 to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or... More
